Navigation Links
New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
Date:10/26/2010

BEDMINSTER, N.J., Oct. 26 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, announced today that an analysis of two pivotal safety and efficacy studies of CAMBIA™ (diclofenac potassium for oral solution) will be presented at the 4th World Congress on Controversies in Neurology Conference (CONy) in Barcelona, Spain.

The new analysis will be presented in a poster (#23) entitled, "Rapid and Sustained Improvement in Migraine Symptoms with a New Powdered Formulation of Diclofenac Potassium for Oral Solution: Results from 2 Randomized Controlled Clinical Trials," and will be presented on Saturday, October 30, 2010 from 7:30 - 8:30 CEST by Alan Rapoport, MD of the David Geffen School of Medicine at University of California, Los Angeles.

About CAMBIA

CAMBIA, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.  Engineered using Dynamic Buffering Technology™ (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research S.A., CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients. For more information, please visit www.cambiarx.com.

About Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders.  Nautilus is backed by Tailwind Capital and Galen Partners.  For more information, please visit www.nautilusneurosciences.com.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... N.Y. , Nov. 26, 2014  BioScrip ® , Inc. ... Smith , President and Chief Executive Officer, will present at the ... , , , Date: , , , Wednesday, ... , 2:50 p.m. EST , , , , Location: , ... About BioScrip, Inc. BioScrip, ...
(Date:11/26/2014)... Nov. 26, 2014  Aridis Pharmaceuticals, Inc., a ... therapies for infectious diseases, announced today the addition ... recognized key opinion leader in the areas of ... board. Founder and Chief Executive Officer, ... Dr. Opal,s extensive experience investigating bacterial toxins and ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
... AACR Highlight Progress in SuperGen's,Oncology-Focused Pre-Clinical Pipeline, ... SuperGen,Inc. today announced that MP470, its multi-targeted ... critical component of,double- stranded DNA repair in ... of,presentations at the 2007 American Association for ...
Cached Medicine Technology:King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 3Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 4Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 5Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 6Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 7
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading diseases, ... place to counter this. However, it doesn’t seem as ... menstrual blood are taken as seriously. , "This ... to handle tampons and menstrual pads while also protecting ... He then created a prototype of the Sani-M, an ...
(Date:11/27/2014)... 2014 "As a nurse I see ... of urinary incontinence," said an inventor from Whiting, N.J. ... specialized accessory to prevent leakage and keep them dry ... urine leakage. This prevents stains on pants, skirts and ... pad ensures that the individual has time to get ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... infections occuring more often than previously believed, study finds ... drug-resistant staph infections are more common, both in and ... study warns. , Methicillin-resistant Staphylococcus aureus (MRSA) infections are ... among people in hospitals and can result in severe ...
... Even though Americans pick up their,toothbrushes for a ... cleaning of their own. Celebrity Dentist Dr. Bill Dorfman ... survey conducted by the,Philips Sonicare brand shows dirty brushes ... this report from Philips (NYSE: PHG ) at:, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today announced that it has,scheduled a conference call and ... ET to discuss operating results for the third quarter ... issue its financial news,release the morning of November 1 ...
... Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... is,inviting everyone with the name of "Walker" in the United States to either,join ... of,Ages" on December 2 in Reseda. According to official census records there,are 663,233 ...
... Oct. 16 Young Innovations, Inc.,(Nasdaq: YDNT ) ... results with a live and on-demand web cast conference ... Time. A live audio,broadcast of the call will be ... live audio broadcast,will also be available through the Company,s ...
... SYMBOL - BCL.P, VANCOUVER, Oct. 16 ... to announce that it has entered into ... 2007 (the "Arrangement,Agreement") with iCo Therapeutics Inc. ... will constitute Beanstalk,s,"Qualifying Transaction" as a capital ...
Cached Medicine News:Health News:Drug-Resistant Staph a Widespread Threat 2Health News:Drug-Resistant Staph a Widespread Threat 3Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 2Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 3Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... for temporary internal drainage from ... bladder. Supplied sterile in peel-open ... CAUTION: Periodic evaluation is advised; ... must not remain indwelling more ...
... Used for catheter or instrument introduction. ... to be peeled away and removed. ... or instrument to be introduced should ... through the sheath. Supplied sterile in ...
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
Medicine Products: